Latest papers

Serotonin modulates sensitivity to reward and negative feedback in a probabilistic reversal learning task in rats.

Healthcare expenditure in severely depressed patients treated with escitalopram, generic SSRIs or venlafaxine in the UK.

The wish to die and 5-year mortality in elderly primary care patients.

Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response.

Open channel block of Kv1.5 currents by citalopram.

Differential effects of acute and repeated citalopram in mouse models of anxiety and depression.

Estradiol valerate elicits antidepressant-like effects in middle-aged female rats under chronic mild stress.

Relationship of residual mood and panic-agoraphobic spectrum phenomenology to quality of life and functional impairment in patients with major depression.

[Depression]

Creatine transporter expression after antidepressant therapy in rats bred for learned helplessness.

Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment.

Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: escitalopram vs paroxetine.

[Personality test and prediction of antidepressive treatment effect in mental illness].

Depression masked as paroxysmal hypertension episodes.

Reduced peripheral brain-derived neurotrophic factor mRNA levels are normalized by antidepressant treatment.

Notch1 signaling related hippocampal neurogenesis in adult poststroke depression rats: a valid index for an efficient combined citalopram and WAY100635 pharmacotherapy.

A pharmacogenetic study of escitalopram in autism spectrum disorders.

Do atypical features affect outcome in depressed outpatients treated with citalopram?

Potential role of glutamate neurotransmission in the pathogenesis of ischemic brain damage and of depression. Effects of L-kynurenine on the survival of the hippocampal neurons and on the corticocerebral blood flow in ischemic animal models.

Relapse prevention and residual symptoms: a closer analysis of placebo-controlled continuation studies with escitalopram in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder.